ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

8,887 trials analyzed so far

Trials that use: Non-inferiority trial design

New to this method? Read the tutorial →

894 results

Relative Bioavailability Study of Emodepside IR-tablets and Solution: Complete Statistical AnalysisIndependent statistical analysis of Relative Bioavailability Study of Emodepside IR-tablets and Solution: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03383523).Phase 1Results postedn = 77NCT03383523
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients: Complete Statistical AnalysisIndependent statistical analysis of Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03873987).Phase 1Results postedn = 102NCT03873987
RELAX-AHF-2Independent statistical analysis of Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 6,600NCT01870778
RELEASEIndependent statistical analysis of PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 41NCT04099888
REPLACE-BGIndependent statistical analysis of A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 226NCT02258373
RESISTIndependent statistical analysis of Aspirin Resistance and Percutaneous Coronary Intervention (PCI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01103440).Phase 2Results postedn = 36NCT01103440
RLICCIndependent statistical analysis of Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 40NCT03512041
ROCKET AFIndependent statistical analysis of ROCKET AF, the randomized phase 3 trial of rivaroxaban versus warfarin for prevention of stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation.Phase 3Results postedn = 14,269NCT00403767
SADHART-CHFIndependent statistical analysis of Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2/3Results postedn = 469NCT00078286
SAILINGComplete statistical analysis of the SAILING phase 3 trial comparing GSK1349572 (dolutegravir) with raltegravir in antiretroviral-experienced, integrase inhibitor-naive adults with HIV infection, including its non-inferiority design, Cochran-Mantel-Haenszel analysis, risk difference, confidence interval,…Phase 3Results postedn = 724NCT01231516
SCALPIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp: primary endpoint results, effect…Phase 4Results postedn = 89NCT00669214
SEAMLESSIndependent statistical analysis of A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 482NCT01303796
SHAPEIndependent statistical analysis of the SHAPE trial comparing radical versus simple hysterectomy with pelvic lymph node dissection for low-risk early stage cervical cancer, including its non-inferiority endpoint, time-to-event analyses, confidence intervals, and…Phase NAResults postedn = 700NCT01658930
SINGLEComplete statistical analysis of the SINGLE phase 3 trial comparing dolutegravir plus abacavir/lamivudine with Atripla in HIV-1 infection, including the Week 48 primary endpoint, later virologic suppression analyses, CD4 outcomes, non-inferiority methodology,…Phase 3Results postedn = 844NCT01263015
SMA-TBIndependent statistical analysis of Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04575519).Phase 2Results postedn = 426NCT04575519
SPARK2Independent statistical analysis of Phase 2B Study Assessing Pain Relief After Replacement of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 226NCT06799845
Split-DoseIndependent statistical analysis of Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 83NCT01653964
SPRING-2Independent statistical analysis of A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 828NCT01227824
STARTIndependent statistical analysis of Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02097641).Phase 2Results postedn = 60NCT02097641
STRENGTHIndependent statistical analysis of Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 13,078NCT02104817
SUPERNOVAIndependent statistical analysis of the randomized phase 2/3 SUPERNOVA trial of AZD3152 and AZD7442 for prevention of COVID-19, including non-inferiority, superiority, Poisson regression, ANOVA, safety, and interpretation of reported results.Phase 2/3Results postedn = 3,882NCT05648110
SURPASSIndependent statistical analysis of Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 859NCT03259074
SURPASS-4Independent statistical analysis of SURPASS-4, a randomized phase 3 trial of once-weekly tirzepatide versus once-daily insulin glargine in participants with type 2 diabetes and increased cardiovascular risk.Phase 3Results postedn = 2,002NCT03730662
SURPASS-6Independent statistical analysis of A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin: primary endpoint results,…Phase 3Results postedn = 1,428NCT04537923
SURTAVIIndependent statistical analysis of SURTAVI, evaluating Medtronic CoreValve System TAVI versus surgical aortic valve replacement for severe symptomatic aortic stenosis, with emphasis on Bayesian non-inferiority methodology and the 24-month primary endpoint.Phase NAResults postedn = 1,746NCT01586910
SUSTAIN 11Complete statistical analysis of SUSTAIN 11, a randomized phase 3 trial comparing semaglutide with insulin aspart when added to metformin and insulin glargine in people with type 2 diabetes.Phase 3Results postedn = 2,274NCT03689374
SUSTAIN-7Independent statistical analysis of the SUSTAIN-7 phase 3 trial comparing semaglutide with dulaglutide as add-on to metformin in subjects with type 2 diabetes, including mixed-effects modeling, non-inferiority and superiority testing, confidence intervals,…Phase 3Results postedn = 1,201NCT02648204
SUSTAIN™ 2Complete statistical analysis of SUSTAIN™ 2, a randomized phase 3 trial comparing once-weekly semaglutide with once-daily sitagliptin as add-on therapy in subjects with type 2 diabetes.Phase 3Results postedn = 1,231NCT01930188
SVIComplete statistical analysis of the randomized phase 3 SVI trial comparing indomethacin alone with indomethacin plus prophylactic pancreatic stent placement for preventing post-ERCP pancreatitis.Phase 3Results postedn = 1,950NCT02476279
SWITCH PROIndependent statistical analysis of A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study:…Phase 4Results postedn = 498NCT03687827
SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.Phase 3Results postedn = 3,040NCT00002651
SYGMA2Complete statistical analysis of SYGMA2, a randomized phase 3 trial evaluating as-needed budesonide/formoterol versus twice-daily budesonide with as-needed terbutaline in adults and adolescents with asthma.Phase 3Results postedn = 4,215NCT02224157
Symplicity AFIndependent statistical analysis of Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 102NCT02064764
TAPERIndependent statistical analysis of Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 4NCT04070157
TeenCoveComplete statistical analysis of the TeenCove trial of mRNA-1273 and mRNA-1273.222 in adolescents 12 toPhase 2/3Results postedn = 4,328NCT04649151
TOPAZIndependent statistical analysis of Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 320NCT02754661
TruEyeTotal1Independent statistical analysis of DAILIES TOTAL1 Versus ACUVUE TruEye - Effects on the Biology of the Ocular Surface and Lid Margin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 118NCT02347631
VERTIS CVIndependent statistical analysis of VERTIS CV (NCT01986881): a stratified Cox non-inferiority analysis of ertugliflozin versus placebo for MACE with a 1.3 hazard-ratio margin, cLDA analyses of A1C change in glycemic sub-studies, secondary…Phase 3Results postedn = 8,246NCT01986881
VIEW 2Complete statistical analysis of VIEW 2, the randomized phase 3 trial comparing aflibercept with ranibizumab in wet age-related macular degeneration, including non-inferiority methodology, ANCOVA, risk differences, and reported week 52 results.Phase 3Results postedn = 1,240NCT00637377
VIEW1A detailed statistical analysis of VIEW1, the randomized phase 3 trial evaluating aflibercept injection versus ranibizumab in patients with macular degeneration, including its non-inferiority design, primary visual-acuity endpoint, ANCOVA analyses, and reported…Phase 3Results postedn = 1,217NCT00509795
VITALITY-HFpEFIndependent statistical analysis of Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03547583).Phase 2Results postedn = 789NCT03547583
WH-PACTIndependent statistical analysis of Implementation of Women's Health Patient Aligned Care Teams: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02039856).Phase NAResults postedn = 3,900NCT02039856
WISARDIndependent statistical analysis of Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With…Phase 3Results postedn = 140NCT05349838
YeapleIndependent statistical analysis of Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01040169).Phase NAResults postedn = 79NCT01040169